Lunai Bioworks Reports Complete Tumor Regression with Second-Generation Dendritic Cell Therapy in Pancreatic Cancer Models
Key Insights
Lunai Bioworks (search) achieved complete regression of both primary and metastatic pancreatic tumors in humanized mouse models using its second-generation allogeneic dendritic cell therapy.
The clinical-grade construct, published in Vaccines journal, maintains therapeutic potency while improving manufacturing attributes for future clinical translation.
The therapy uses engineered dendritic cells derived from CD34+ (search) hematopoietic stem cells that overexpress CD40L (search), CD93 (search), and CXCL13 (search) to activate immune responses against cancer.
Lunai Bioworks (search) has announced a major breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models using its second-generation allogeneic dendritic cell therapy. The results were published in a peer-reviewed Brief Report in the journal Vaccines on November 2, 2025.
The AI-powered drug discovery company's latest study details the development of a clinical-grade dendritic cell construct that demonstrated complete tumor regression in humanized models of pancreatic cancer (search), one of the deadliest cancers known for late diagnosis and resistance to conventional treatments.
Enhanced Clinical-Grade Platform
The second-generation therapy builds upon Lunai's earlier research published in July 2025, which first demonstrated potent anti-tumor activity using CD34+ (search) hematopoietic stem cell-derived dendritic cells engineered to overexpress CD40L (search), CD93 (search), and CXCL13 (search). While the initial study utilized a research-grade lentiviral vector, the latest report describes an optimized, clinically compliant construct that preserves equivalent efficacy while improving design and manufacturing attributes.
The enhanced construct features a strong mammalian promoter and enhanced genetic elements to drive expression of key immune-modulating molecules. In preclinical testing, the therapy triggered robust activation of cytotoxic T cells and NK cells, leading to complete regression of both primary and metastatic pancreatic tumors that mirrored outcomes achieved with the original research-grade product.
Mechanism and Therapeutic Potential
Lunai's therapy employs engineered dendritic cells—specialized immune cells created from stem cells—that are genetically enhanced to activate the body's immune system against cancer. The allogeneic approach allows for off-the-shelf treatment options, potentially addressing manufacturing and accessibility challenges associated with autologous cell therapies.
While evaluated specifically in pancreatic cancer (search) models, the therapeutic potential of the allogeneic dendritic cell product extends to a broad range of solid tumors, according to the company's findings.
Clinical Translation Pathway
"These findings demonstrate that our vector optimization strategy maintains therapeutic potency while bringing our allogeneic DC platform to the threshold of IND-enabling studies," said David Weinstein, CEO of Lunai Bioworks (search). "This represents an important inflection point as we move from research innovation to clinical translation—positioning Lunai at the forefront of next-generation cell-based immunotherapies."
The clinical-compliant design and demonstrated efficacy provide critical evidence for advancing ongoing partnering conversations for the therapy platform. The company indicates that the optimized construct brings the platform closer to investigational new drug application-enabling studies.
The full research article, titled "Modified Hematopoietic Stem Cell-Derived Dendritic Cell Therapy Retained Tumor-Inhibitory Function and Led to Regression of Primary and Metastatic Pancreatic Tumors in Humanized Mouse Models," is available in Vaccines journal.